Oleguer Castillo

Barcelona, CT 08036, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.

HER2DX genomic assay in HER2-positive early breast cancer treated with trastuzumab and pertuzumab: A correlative analysis from a real-world cohort.

Journal: Breast (Edinburgh, Scotland)

Published: January 12, 2026

Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.

Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane.

Journal: NPJ breast cancer

Published: September 15, 2025

Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.

Pembrolizumab and Paclitaxel in HR+/HER2- Breast Cancer with HER2-Enriched or Basal-Like Subtypes.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 11, 2025

Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy.

Journal: ESMO open

Published: July 11, 2025

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Pembrolizumab and Paclitaxel in Patients with HR+/HER2- Breast Cancer with HER2-Enriched or Basal-like Subtypes.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 11, 2025

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trial.

Journal: ESMO open

Published: June 16, 2025

Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial.

Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial.

Journal: International journal of radiation oncology, biology, physics

Published: January 30, 2025

Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study.

Prevalence and clinical impact of germline pathogenic variants in breast cancer: a descriptive large single-center study.

Journal: ESMO open

Published: December 06, 2024

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab.

Journal: NPJ breast cancer

Published: September 28, 2024

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.

Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer.

Journal: Scientific reports

Published: March 06, 2024

Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.

Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.

Journal: ESMO open

Published: December 24, 2023

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab.

Journal: JAMA oncology

Published: April 27, 2023

Showing 1-12 of 15

Last Updated: 09/26/2026